Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Despite strong vetting for disease activity, only 10% of candidate new molecular entities in early stage clinical trials are eventually approved. Analyzing historical pipeline data, Nelson et al. 2015 (Nat. Genet.) concluded pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approved drugs. Taking advantage of recent clinical development advances and rapid growth in GWAS datasets, we extend the original work using updated data, test whether genetic evidence predicts future successes and introduce statistical models adjusting for target and indication-level properties. Our work confirms drugs with genetically supported targets were more likely to be successful in Phases II and III. When causal genes are clear (Mendelian traits and GWAS associations linked to coding variants), we find the use of human genetic evidence increases approval by greater than two-fold, and, for Mendelian associations, the positive association holds prospectively. Our findings suggest investments into genomics and genetics are likely to be beneficial to companies deploying this strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Estimated effect of evidence from human genetic studies on the probability of advancing in clinical development. A: Partitioning Pharmaprojects, OMIM, and GWAS Catalog into training data available to Nelson et al. 2015 and validation sets. We use validation set Pipeline Progression, consisting of target-indication pairs assigned a clinical phase in 2013, to determine whether gene target-indication pairs with genetic evidence were more likely to advance to the next pipeline phase from 2013-2018. Pharmaprojects target-indication pairs absent from or assigned an unknown clinical phase in the Nelson et al. dataset form the New Pipeline replication set. Pharmaprojects target-indication pairs approved prior to 2013 or with unknown phase in our dataset are not part of any replication set. B: Our estimates of the effect of genetic evidence on gene target-indication pair progression compared to values reported by Nelson et al. 2015 [3] in validation sets New Pipeline (drugs and indications > 2013, 2013 inactive drugs) New Genetic (only new genetic information > 2013) Pipeline Progression, and in the full updated dataset (Full Data). Estimates falling close to the identity line (shown in black) are consistent between the two analyses.](https://figures.cochat.ai/paper-figures/fbfe5599a9364dd7aab42f07a9e12b6a/are-drug-targets-with-genetic-support-twice-as-likely-to-be-approved-revised-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is supported by drug candidates with genetically supported targets being significantly more likely to progress through phased clinical trials (9, 10).”
From Identification of human gene research articles with wrongly identified nucleotide sequences (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
An Information-Theoretic Definition of Similarity
Lin, D. (1998) · International Conference on Machine Learning · Cited by 4,697
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1229 · Cited by 2,707
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Watanabe, S. (2010) · arXiv (Cornell University) · doi:10.48550/arxiv.1004.2316 · Cited by 2,226
Research works printed but not linked: 1
- J MacArthur, 2016, The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog), Nucleic Acids Research, 45, D896, 10.1093/nar/gkw1133 · DOI · Paper page
Cited by
Items 601–648 of 648
Proteogenomic analysis of 5,411 plasma proteins in sickle cell disease patients
Groza, C., Chignon, A., Lo, K. S., Bellegarde, V., Bartolucci, P., & Lettre, G. (2026) · PLoS Genetics · doi:10.64898/2026.04.06.26350255
Grand, Q. L. (2022) · theses.fr (ABES) · doi:10.70675/57471dc3zf5a3z409fz9460z8caebe3cff26
Sooknah, M., Srinivasan, R., Sankarapandian, S., Chen, Z., & Xu, J. (2026) · medRxiv · doi:10.64898/2026.04.10.26350624
Maisto, N., Dashtiani, S., d’Ettorre, A., di Nuzzo, S., & Mango, D. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-026-03165-5
Disentangling the contribution of disease genes to drug therapeutic and side effectsPreprint
Lalagkas, P. N., & Melamed, R. (2026) · medRxiv · doi:10.64898/2026.05.04.26352378
Li, T., & Wei, Q. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261449014
A transformer model explaining mechanisms of drug therapeutic and adverse effectsPreprint
Ke, J., & Melamed, R. (2026) · medRxiv · doi:10.64898/2026.05.11.26352917
Genetic Identification of Potential Drug Targets for Dental Caries: A Mendelian Randomization Study
毕俊蕾, Liu, A., Zhang, N., Chen, Y., Liu, C., Zhu, Y., Wen, H., & Ma, C. (2026) · Health Science Reports · doi:10.1002/hsr2.72546
ter Kuile, A., Finan, C., Chopade, S., van Vugt, M., Hukerikar, N., Barral, S., Stringaris, A. K., Schmidt, A. F., Kuchenbaecker, K. B., & Pingault, J. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04137-9
The anti-inflammatory efficacy of melanocortin drugs is influenced by genetic variation at MC1R
Khodeneva, N., Davan-Wetton, C. S. A., Jonassen, T. E. N., Perretti, M., & Montero‐Melendez, T. (2026) · Scientific Reports · doi:10.1038/s41598-026-57399-0
Felici, B., Chen, S., Yuan, M., Jiang, X., Ip, S., Rudd, J. H. F., & Inouye, M. (2026) · Cell Genomics · doi:10.1016/j.xgen.2026.101282
Fundamentals of dermatologic drug discovery
Grada, A. A. (2026) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2026.1777138
Colantuoni, M., Xiao, Q., Aziz, N. A., Aguiar, V. R. C., Djeddi, S., Liao, Y., Fernandez‐Salinas, D., Kim, T., Lewandowski, L. B., Gu, J., et al. (2026) · medRxiv · doi:10.64898/2026.07.28.26359131
Ma, J., Yang, S., & Du, Y. (2026) · BMC Musculoskeletal Disorders · doi:10.21203/rs.3.rs-10422413/v1
Veerabhadraiah, S. R., Ma, Y., Hegde, S., Stark, A. W., & Jurynec, M. J. (2026) · ACS Omega · doi:10.1021/acsomega.6c04569
THBKG: A Temporal Biomedical Knowledge Graph for Decision-Aligned Clinical Advancement PredictionPreprint
Siu, P. C., Cabrera, C., Mudaliar, M., & Zubiaga, A. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2608.05982
Jensen, S., Vos, P., & Olsen, L. (2024) · Pharmacophore · doi:10.51847/exrfjypbrw
Chang, M., Martin, A.-S., Oduor, R., & Lehmann, T. (2025) · Pharmacophore · doi:10.51847/wwzoralyut
G2DR: a genotype-first framework for genetics-informed target prioritization and drug repurposing
Muneeb, M., & Ascher, D. B. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag427 · Cited by 1
Costa, R., Watson, E., Benziane, K., & Silva, A. (2025) · Pharmacophore · doi:10.51847/49pn9gi36y
Zhang, J., Liu, Q., 诸叶平, Xia, L., Wang, K., Guo, Y., Gong, L., Liu, Z., Qin, Z. S., Shi, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76649-3
Wright, E., Bennett, C., Turner, J., & Harris, O. (2025) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/z5ioypbb4u
Nkosi, T., Molefe, L., Dlamini, S., Mokoena, A., & Ndlovu, K. (2026) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/fufncppkde
Zhao, Y., Chen, L., Fauzi, A., & Hayati, N. (2025) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/xx6cxggypd
Walker, J., Harris, O., & Wilson, G. (2026) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/5gtariiafd
The Genetic Architecture of Chronic Cough: From Sensory Hypersensitivity to Treatable Trait
Dong, R., Zhang, M., & Morice, A. H. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00382-x
Rare disease benchmarks: Investment professionals’ accuracy and beliefs
Ilicki, J., & Spicer, A. J. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104792
Schneider, N., Frank, T., Müller, A., & Meier, C. (2026) · Specialty journal of Pharmacognosy Phytochemistry and Biotechnology · doi:10.51847/9uwevbmrwk
Mo, X., Sun, D., Li, F., Wang, D., Deng, Y., & Liao, Y. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117451
Incentivizing challenging drug discovery: from reducing failure to quantifying uncertainty
Moro, S. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2733199
Kapoor, S., & Verma, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40338-5.00001-9
Seo, Y., & Woo, J. (2026) · Pharmaceuticals · doi:10.3390/ph19101510
Voller, B., Woodward, R. M., Murrin, O., Delgado, J., Türkmen, D., Hopkins, R., Violán, C., Mancini, M., Farmer, L., Boddy, K., et al. (2026) · medRxiv · doi:10.64898/2026.09.28.26364012
Packer, A. E., Austin, L., Williams, D. M., Taylor‐Bateman, V., & Anderson, E. L. (2026) · medRxiv · doi:10.64898/2026.09.22.26363326
The role of interleukin 6 in the development of cardiovascular pathology
Nasonov, E. L., Fomicheva, O. A., & Попкова, Т. В. (2026) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2026-41-3-12-18
Genetic susceptibility and clinical validation of ICAM-5 in immune-mediated non-infectious uveitis
Zhuang, Z., Hu, P., Hong, X., Lin, T., Yu, Y., Jia, X., Su, X., Su, B., Shi, W., & Hu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1948697
Ali, A. B., Gharbi, S., & Jebali, N. (2025) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/kl3hk54rmu
DrugTargetWorld: A Synthetic Biobank for Training and Benchmarking AI ScientistsPreprint
Margolis, S., Schmiedmayer, P., Huang, A., Chen, E., Bhattacharjee, I., Shah, A., Viggiano, B., Cao, F., Reddy, S., Xia, R., et al. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2610.09558
Shen, L., Qin, C., Deng, Z.-L., Yu, Q., Deng, R., Chen, M., Hu, T., Wang, X., Lei, B., Chen, Y., et al. (2026) · Mediators of Inflammation · doi:10.1155/mi/5998779
Arehart, C. H., & Evans, L. M. (2026) · medRxiv · doi:10.64898/2026.10.05.26364047
Johnson, E., Smith, R., Brown, L., & Miller, K. (2026) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/1dveyh5v5f
Altahla, R., Wang, Z., Rong, S., Li, C., Jadgal, N., Mehran, M. J., Bolideei, M., & Alshorman, J. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70223
Kostiuk, K., Igumnov, D., Fedichev, P. O., & Feizi, A. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag788
Brosseau, N., Pincez, T., Lo, K. S., Lo, C., Beaudoin, M., & Lettre, G. (2026) · Communications Biology · doi:10.1038/s42003-026-11204-w
Genetically informed search for potential osteoarthritis drug targets across the proteome
Liu, W., Zuckerman, B. P., Schuermans, A., Orozco, G., Honigberg, M. C., Bowes, J., O’Neill, T. W., & Zhao, S. S. (2026) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2026.100890
Metadata
- Authors
- King, E. A., Davis, J. W., & Degner, J. F.
- Affiliations
- AbbVie (United States) (US)
- Corresponding author
- King, Emily A.
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-12-12
- Volume
- 15
- Issue
- 12
- Pages
- e1008489
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC6907751
- OpenAlex
- W2995245946
- Cited by
- 649
- References
- 40
- Citations by year
- 2026: 71 · 2025: 97 · 2024: 132 · 2023: 118 · 2022: 92 · 2021: 85 · 2020: 47 · 2019: 6
- FWCI
- 34.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- drug approval, therapeutic target, genetic evidence, drug development pipeline, new chemical entities, monogenic disorders, genome-wide association study, coding variants, drug development investment
- MeSH terms
- Pharmacogenomic Variants, Humans, Phenotype, Models, Statistical, Drug Approval, Genetic Predisposition to Disease, Genomics, Databases, Genetic, Quantitative Trait Loci, Genome-Wide Association Study, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.